Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 10.14%.

  • Kiniksa Pharmaceuticals International's EBITDA Margin rose 213700.0% to 10.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.99%, marking a year-over-year increase of 83600.0%. This contributed to the annual value of 10.25% for FY2024, which is 154400.0% down from last year.
  • Kiniksa Pharmaceuticals International's EBITDA Margin amounted to 10.14% in Q3 2025, which was up 213700.0% from 11.44% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin registered a high of 226.07% during Q3 2022, and its lowest value of 538.88% during Q2 2021.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin had a median value of 9.29% in 2024 and averaged 51.5%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EBITDA Margin surged by 4792000bps in 2022, and later crashed by -2467500bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin (Quarter) stood at 193.94% in 2021, then skyrocketed by 98bps to 3.09% in 2022, then soared by 1081bps to 30.27% in 2023, then tumbled by -124bps to 7.35% in 2024, then surged by 238bps to 10.14% in 2025.
  • Its EBITDA Margin stands at 10.14% for Q3 2025, versus 11.44% for Q2 2025 and 6.2% for Q1 2025.